By Pierre Bertrand


Novartis said that its U.S. patent for Entresto was upheld by the U.S. Court of Appeals.

The Swiss pharmaceutical company said the court affirmed the validity of its patent on Entresto and combinations of sacubitril and valsartan.

The ruling comes after the company said in July 2023 that a U.S. District Court in Delaware had ruled the patent to be invalid.

The patent's pediatric exclusivity period expires in July 2025, Novartis said Monday.

It added that were no generic versions of Entresto available in the country.


Write to Pierre Bertrand at pierre.bertrand@wsj.com


(END) Dow Jones Newswires

01-13-25 0148ET